Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
Charles Chuanhai GuoiD, Tadeusz MajewskiiD, Li ZhangiD, Hui YaoiD, Jolanta E. Bondaruk, Yan WangiD, Shizhen ZhangiD, Ziqiao WangiD, June Goo Lee, Sangkyou Lee, David E. Cogdell, Miao ZhangiD, Peng WeiiD, H. Barton Grossman, Ashish M. KamatiD, Jonathan J. Duplisea, James E. FergusoniD, He HuangiD, Vipulkumar Dadhania, Jianjun GaoiD, Colin P. DinneyiD, John N. WeinsteiniD, Keith Baggerly, David James McConkeyiD, Bogdan A. CzerniakiD
Abstract
The sarcomatoid variant of urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARCs and 84 cases of conventional urothelial carcinomas (UCs), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs showed a distinct mutational landscape with enrichment of TP53, RB1, and PIK3CA mutations. They were related to the basal molecular subtype of conventional UCs and could be divided into epithelial/basal and more clinically aggressive mesenchymal subsets based on TP63 and its target genes expression levels. Other analyses revealed that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of cell cycle and EMT networks, and nearly half exhibited a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 145
- FWCI
- 17.18
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma.
Yujiro Hayashi, Roy Elias, … Burles Avner Johnson·bioRxiv·Oct 2, 2026
- Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer
M. Garioni, L. Blukacz, … C. Le Magnen·bioRxiv·Feb 20, 2023
- Field cancerization impacts tumor development, T-cell exhaustion and clinical outcomes in bladder cancer
T. Strandgaard, I. Nordentoft, … L. Dyrskjot·bioRxiv·Feb 20, 2023
- Bidirectional Crosstalk Between Bladder Cancer Cells and Normal Fibroblasts Drives Phenotypic Reprogramming and Modulates Chemosensitivity
Jinhui Gao, Cindy Xinyu Ji, … Jennifer L. Rohn·bioRxiv·Sep 9, 2025
- TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway
P. V. Iyengar, D. L. Marvin, … P. ten Dijke·bioRxiv·Oct 12, 2020
- ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition
J. E. Ferguson, H. Rehman, … S. Varambally·bioRxiv·Jan 12, 2021